Cargando…

A Six-Year Analysis of Biological Therapy for Severe Psoriasis in a Lithuanian Reference Centre of Dermatovenereology

Background and Objectives: Biological therapy is widely used for the treatment of severe psoriasis. The objective of this study was to evaluate the efficacy and safety of biological therapy for patients with severe psoriasis. Materials and Methods: A retrospective study of 79 patients with severe ps...

Descripción completa

Detalles Bibliográficos
Autores principales: Raudonis, Tadas, Gliebute, Akvile, Grigaityte, Anna Greta, Lukosiunaite, Zivile, Karmaziene, Tatjana, Grigaitiene, Jurate
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7353857/
https://www.ncbi.nlm.nih.gov/pubmed/32512854
http://dx.doi.org/10.3390/medicina56060275
_version_ 1783557971423264768
author Raudonis, Tadas
Gliebute, Akvile
Grigaityte, Anna Greta
Lukosiunaite, Zivile
Karmaziene, Tatjana
Grigaitiene, Jurate
author_facet Raudonis, Tadas
Gliebute, Akvile
Grigaityte, Anna Greta
Lukosiunaite, Zivile
Karmaziene, Tatjana
Grigaitiene, Jurate
author_sort Raudonis, Tadas
collection PubMed
description Background and Objectives: Biological therapy is widely used for the treatment of severe psoriasis. The objective of this study was to evaluate the efficacy and safety of biological therapy for patients with severe psoriasis. Materials and Methods: A retrospective study of 79 patients with severe psoriasis, who have been treated with biological therapy between 2012 and 2018, was conducted. During this study, the following data were collected and evaluated: sex, age, body mass index (BMI), duration of illness, the results of treatment with biological therapy, concomitant therapy, Psoriasis Area and Severity Index (PASI) and adverse events. Results: In total, 74.7% (n = 59) of subjects were male. Their overall average age was 47.4 ± 11.4 (range: 18–73) years. Their baseline BMI was 27.6 ± 5.9, which increased to 29.6 ± 4.5 after 6 years of treatment. The mean duration of psoriasis was 25.7 ± 12.5 years. In total, 39.2% (n = 31) of subjects received infliximab, 36.7% (n = 29)—etanercept, 24.1% (n = 19)—ustekinumab. The treatment duration for infliximab, etanercept and ustekinumab was 201.6 ± 86.8, 156.2 ± 137.4 and 219.1 ± 95.7 weeks (p < 0.01), respectively. Overall, 65.8% (n = 52) of subjects were also on methotrexate; 30.8% (n = 16) of them discontinued it due to clinical improvement (31.3% (n = 5)), impaired liver function (31.3% (n = 5)), and intolerance (25% (n = 4)). Baseline PASI was 20.8 ± 8.8. PASI 50 was achieved by 96.2% (n = 76) of patients at week 11, PASI 75 by 86.1% (n = 68) at week 16, PASI 90 by 54.4% (n = 43) at week 35, and PASI 100 by 13.9% (n = 11) at week 33. The overall incidence rate of adverse events was 0.362 per patient year of follow-up. Conclusion: Biological therapy is an effective and safe treatment for patients with severe psoriasis.
format Online
Article
Text
id pubmed-7353857
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-73538572020-07-21 A Six-Year Analysis of Biological Therapy for Severe Psoriasis in a Lithuanian Reference Centre of Dermatovenereology Raudonis, Tadas Gliebute, Akvile Grigaityte, Anna Greta Lukosiunaite, Zivile Karmaziene, Tatjana Grigaitiene, Jurate Medicina (Kaunas) Review Background and Objectives: Biological therapy is widely used for the treatment of severe psoriasis. The objective of this study was to evaluate the efficacy and safety of biological therapy for patients with severe psoriasis. Materials and Methods: A retrospective study of 79 patients with severe psoriasis, who have been treated with biological therapy between 2012 and 2018, was conducted. During this study, the following data were collected and evaluated: sex, age, body mass index (BMI), duration of illness, the results of treatment with biological therapy, concomitant therapy, Psoriasis Area and Severity Index (PASI) and adverse events. Results: In total, 74.7% (n = 59) of subjects were male. Their overall average age was 47.4 ± 11.4 (range: 18–73) years. Their baseline BMI was 27.6 ± 5.9, which increased to 29.6 ± 4.5 after 6 years of treatment. The mean duration of psoriasis was 25.7 ± 12.5 years. In total, 39.2% (n = 31) of subjects received infliximab, 36.7% (n = 29)—etanercept, 24.1% (n = 19)—ustekinumab. The treatment duration for infliximab, etanercept and ustekinumab was 201.6 ± 86.8, 156.2 ± 137.4 and 219.1 ± 95.7 weeks (p < 0.01), respectively. Overall, 65.8% (n = 52) of subjects were also on methotrexate; 30.8% (n = 16) of them discontinued it due to clinical improvement (31.3% (n = 5)), impaired liver function (31.3% (n = 5)), and intolerance (25% (n = 4)). Baseline PASI was 20.8 ± 8.8. PASI 50 was achieved by 96.2% (n = 76) of patients at week 11, PASI 75 by 86.1% (n = 68) at week 16, PASI 90 by 54.4% (n = 43) at week 35, and PASI 100 by 13.9% (n = 11) at week 33. The overall incidence rate of adverse events was 0.362 per patient year of follow-up. Conclusion: Biological therapy is an effective and safe treatment for patients with severe psoriasis. MDPI 2020-06-04 /pmc/articles/PMC7353857/ /pubmed/32512854 http://dx.doi.org/10.3390/medicina56060275 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Raudonis, Tadas
Gliebute, Akvile
Grigaityte, Anna Greta
Lukosiunaite, Zivile
Karmaziene, Tatjana
Grigaitiene, Jurate
A Six-Year Analysis of Biological Therapy for Severe Psoriasis in a Lithuanian Reference Centre of Dermatovenereology
title A Six-Year Analysis of Biological Therapy for Severe Psoriasis in a Lithuanian Reference Centre of Dermatovenereology
title_full A Six-Year Analysis of Biological Therapy for Severe Psoriasis in a Lithuanian Reference Centre of Dermatovenereology
title_fullStr A Six-Year Analysis of Biological Therapy for Severe Psoriasis in a Lithuanian Reference Centre of Dermatovenereology
title_full_unstemmed A Six-Year Analysis of Biological Therapy for Severe Psoriasis in a Lithuanian Reference Centre of Dermatovenereology
title_short A Six-Year Analysis of Biological Therapy for Severe Psoriasis in a Lithuanian Reference Centre of Dermatovenereology
title_sort six-year analysis of biological therapy for severe psoriasis in a lithuanian reference centre of dermatovenereology
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7353857/
https://www.ncbi.nlm.nih.gov/pubmed/32512854
http://dx.doi.org/10.3390/medicina56060275
work_keys_str_mv AT raudonistadas asixyearanalysisofbiologicaltherapyforseverepsoriasisinalithuanianreferencecentreofdermatovenereology
AT gliebuteakvile asixyearanalysisofbiologicaltherapyforseverepsoriasisinalithuanianreferencecentreofdermatovenereology
AT grigaityteannagreta asixyearanalysisofbiologicaltherapyforseverepsoriasisinalithuanianreferencecentreofdermatovenereology
AT lukosiunaitezivile asixyearanalysisofbiologicaltherapyforseverepsoriasisinalithuanianreferencecentreofdermatovenereology
AT karmazienetatjana asixyearanalysisofbiologicaltherapyforseverepsoriasisinalithuanianreferencecentreofdermatovenereology
AT grigaitienejurate asixyearanalysisofbiologicaltherapyforseverepsoriasisinalithuanianreferencecentreofdermatovenereology
AT raudonistadas sixyearanalysisofbiologicaltherapyforseverepsoriasisinalithuanianreferencecentreofdermatovenereology
AT gliebuteakvile sixyearanalysisofbiologicaltherapyforseverepsoriasisinalithuanianreferencecentreofdermatovenereology
AT grigaityteannagreta sixyearanalysisofbiologicaltherapyforseverepsoriasisinalithuanianreferencecentreofdermatovenereology
AT lukosiunaitezivile sixyearanalysisofbiologicaltherapyforseverepsoriasisinalithuanianreferencecentreofdermatovenereology
AT karmazienetatjana sixyearanalysisofbiologicaltherapyforseverepsoriasisinalithuanianreferencecentreofdermatovenereology
AT grigaitienejurate sixyearanalysisofbiologicaltherapyforseverepsoriasisinalithuanianreferencecentreofdermatovenereology